


Azerbaijan

Factor VIII per capita compared to other countries

This country fact sheet accompanies the EHC heat map and gives you further information on the country's progress over the various EHC surveys.

Here, you will see how the FVIII international units provision has evolved and compares to other countries. You will also find the same parameters as in the heat map.



Change since previous survey: ▲ Improvement ▼ Decline

		2009		2012		2015		2018
International units per capita	Factor VIII	0.00	▲	1.96	▼	1.89	▼	1.72
	Factor IX	0.00	▲	0.16	▲	0.21	▼	0.00
Organisation of care	Comprehensive Care Centres (CCC's)	Yes		Yes		Yes		Yes
	Haemophilia Treatment Centres	Yes		Yes		Yes		Yes
	National Haemophilia Council or Co-ordinating Group	No		No	▲	Yes		Yes
	Number of groups in decision-making on haemophilia care	0	▲	3	▼	2	▲	3
	Number of groups choosing haemophilia treatment products	0	▲	2		2		2
	National Tender for procurement of factor concentrates			Yes		Yes		Yes
Treatment regimens	Home Treatment			Yes		Yes		Yes
	% of people with haemophilia using home treatment			<10%		<10%	▲	10-50%
	Treatment delivered to the patient's home			No		Some		Unknown
	Prophylaxis treatment availability			Some		Some		Some
	Children currently on prophylaxis (%)			1-25%		1-25%		1-25%
	Adults currently on prophylaxis (%)			1-25%		1-25%		1-25%
Access to specialist services	Emergency medicine and acute surgery			Yes		Yes		Yes
	Paediatrics			Yes		Yes		Yes
	Infectious disease specialists (especially HIV)			Never	▲	Sometimes	▲	Yes
	Hepatology			Sometimes		Sometimes	▲	Yes
	Rheumatology			Yes	▼	Sometimes	▲	Yes
	Orthopaedics			Yes		Yes		Yes
	Physiotherapy			Yes		Yes		Yes
	Dentistry			Yes		Yes		Yes
	Obstetrics and Gynaecology			Yes		Yes		Yes
	Genetics			Never		Never		Never
	Social and psychological support			Sometimes		Sometimes		Sometimes
	Pain management			Yes	▼	Sometimes	▲	Yes
	General surgery			Yes		Yes		Yes
	Urology			Yes		Yes		Yes
Share of Expected Bleeding Disorder Prevalence	Haemophilia A	91%	▲	115%	▼	111%	▲	117%
	Haemophilia B	13%	▲	35%	▲	44%	▲	47%
	von Willebrand Disease	2%	▼	2%	▼	2%	▲	2%
Haemophilia replacement therapy	Plasma-derived factor concentrate	Always		Always		Always		Always
	Recombinant factor concentrate	Never	▲	Always	▼	Rarely		Rarely
	Plasma	Rarely		Rarely		Rarely		Rarely
	Cryoprecipitate	Never	▼	Rarely		Rarely		Rarely
VWD replacement therapy	Plasma-derived factor concentrate			Rarely	▲	Always		Always
	DDAVP					Rarely	▲	Always
	Plasma			Rarely		Rarely	▼	Always
	Cryoprecipitate					Rarely	▼	Always